“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
Foley Board Taps Daljit Doogal for Second Term as Chair and CEO
Daljit Doogal, the Detroit partner who will start his second